Introduction: Follicular lymphoma (FL) is a heterogeneous disease, and identifying high-risk patients early is crucial for optimal management. This study aimed to evaluate the prognostic significance of interim positron emission tomography/computed tomography (PET/CT) in newly diagnosed FL patients undergoing first-line treatment.Methods: This single-center, retrospective study included 103 patients with newly diagnosed FL who underwent interim PET/CT. The primary endpoint was progression-free survival (PFS). The prognostic value of positive interim PET/CT, Deauville scores, and maximum standardized uptake values (SUVmax) were analyzed among other clinical features.Results: A total of 30 patients (29.1%) were deemed interim PET/CT-positive. The interim PET/CT-positive group demonstrated a significantly shorter median PFS compared to the interim PET/CT-negative group (17 months vs. not reached, respectively;p< 0.0001). Similarly, patients with Deauville scores of 1–3 had better PFS, with median survival not yet reached, while those with higher Deauville scores exhibited poorer progression-free survival and a median survival of 18 months. Notably, patients with an interim PET/CT SUVmax exceeding 3.365 experienced significantly shorter median survival compared to those with lower values.Discussion: Our findings support the use of interim PET/CT as a prognostic tool in FL. These results are consistent with other studies, although some debate exists regarding the optimal PET/CT metric. Further research is needed to validate these findings and explore personalized treatment strategies based on interim PET/CT results.
引言：滤泡性淋巴瘤（FL）是一种异质性疾病，早期识别高危患者对于优化治疗至关重要。本研究旨在评估中期正电子发射断层扫描/计算机断层扫描（PET/CT）对接受一线治疗的新诊断FL患者的预后意义。 方法：这项单中心回顾性研究纳入了103例接受中期PET/CT检查的新诊断FL患者。主要终点是无进展生存期（PFS）。研究分析了中期PET/CT阳性、Deauville评分及最大标准化摄取值（SUVmax）等临床特征的预后价值。 结果：共有30例患者（29.1%）被判定为中期PET/CT阳性。与中期PET/CT阴性组相比，阳性组的中位PFS显著缩短（分别为17个月与未达到；p<0.0001）。同样，Deauville评分为1-3分的患者PFS更佳（中位生存期尚未达到），而评分较高的患者无进展生存较差，中位生存期为18个月。值得注意的是，中期PET/CT SUVmax超过3.365的患者，其中位生存期显著低于数值较低者。 讨论：我们的研究结果支持将中期PET/CT作为FL的预后评估工具。尽管关于最佳PET/CT评估指标仍存在争议，但这些结果与其他研究一致。未来需要进一步研究验证这些发现，并探索基于中期PET/CT结果的个体化治疗策略。
肿瘤(癌症)患者之家